Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Increase Transparency of NDA Review Process: Mr Nagatsuma
June 28, 2010
- Afinitor Extends PFS in Advanced pNET Patients in PIII: Novartis
June 28, 2010
- Astellas' Brazilian Affiliate Starts Operation
June 28, 2010
- FDA Orders Eisai, Sepracor to Stop Using Some Promotional Materials
June 28, 2010
- Kansai Bio-Promotion Allies with Flanders Bio
June 28, 2010
- ACRONET Invests in Chinese CRO NANDACRO
June 28, 2010
- CMIC Decides to Develop Sodium Phenylbutyrate
June 28, 2010
- NCCHD Considers Gene Therapy for Chronic Granuloma
June 28, 2010
- FTC Warns Nakazawa Ujike for Possible Anti-Monopoly Act Infringements
June 28, 2010
- Interim Analysis Confirms Safety of Tykerb in PIII for Stomach Cancer
June 28, 2010
- Merck Serono to Launch More Than 6 Products in 2012 Onward
June 28, 2010
- JGA's Generics Information Supply System Gets on Track
June 21, 2010
- Eribulin Prolongs OS but Not PFS
June 21, 2010
- Leptin Replacement Therapy for Lipoatrophy Recommended as Advanced Therapy
June 21, 2010
- 635 MSs to Take 1 Exam for Certification
June 21, 2010
- Eribulin Shows High ORR in Japanese Patients
June 21, 2010
- Mr Kan Stresses Need for Strong Economy, Strong Finance, and Strong Social Security
June 21, 2010
- NDA Review Period Drastically Shortened in FY2009: PMDA
June 21, 2010
- New c-Met Inhibitor Prolongs PFS in PII for NSCLC
June 21, 2010
- ASCO, FDA Open “Expanded Access”Website on Use of Unapproved Drugs
June 21, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…